Do urologists apply benign prostatic hyperplasia clinical practice guidelines? Survey on the complementary investigation request modalities in France;Les urologues appliquent-ils les recommandations sur la prise en charge de l'hyperplasie bénigne de la prostate? Enquête sur les modalités de prescription des examens complémentaires en France

Progres en Urologie

Volumn 14, Issue 3, 2004, Pages 320-325

  De La Taille, Alexandre ^a   Desgrandchamps, François ^b   Saussine, Christian ^c   Lukacs, Bertrand ^d   Haillot, Olivier ^e  

^a HENRI MONDOR HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL CIVIL   (France)

^d HÔPITAL TENON   (France)

^e CHU BRETONNEAU   (France)

Author keywords

BPH; ECBU; IPSS; PSA; Recommendations

Indexed keywords

CREATININE;

AGE DISTRIBUTION; ANTIGEN DETECTION; CLINICAL PRACTICE; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DATA ANALYSIS; DIAGNOSTIC APPROACH ROUTE; FIBERSCOPE ENDOSCOPY; HEALTH SURVEY; HOSPITAL PHYSICIAN; HUMAN; INFORMATION PROCESSING; INTERVIEW; MEDICAL ASSESSMENT; MEDICAL EXAMINATION; MEDICAL SPECIALIST; MICTURITION CYSTOURETHROGRAPHY; PRACTICE GUIDELINE; PRIVATE PRACTICE; PROSTATE HYPERTROPHY; PUBLICATION; QUESTIONNAIRE; RENOGRAPHY; REVIEW; SCORING SYSTEM; TRANSRECTAL ULTRASONOGRAPHY; URINALYSIS; URINE CULTURE; UROFLOWMETRY;

ADULT; AGED; DIAGNOSTIC TECHNIQUES, UROLOGICAL; FRANCE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PROSTATIC HYPERPLASIA; QUESTIONNAIRES;

EID: 4143070304     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. ANAES: Prise en charge diagnostic et thérapeutique de l'hypertrophie bénigne de la prostate. Texte de recommandation de l'ANAES 2003 (http://www.anaes.fr)
2. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J. Urol., 2003 ; 170 : 530-47.
3. BARRY M.J., FOWLER F.J. JR, O'LEARY M.P., BRUSKEWITZ R.C., HOLTGREWE H.L., MEBUST W.K., COCKETT A.T. : The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol., 1992 ; 148 : 1549-1557.
4. CABANA M.D., RAND C.S., POWE N.R., WU A.W., WILSON M.H., ABBOUD P.A., RUBIN H.R. : Why don't physicians follow clinical practice guidelines ? A framework for improvement. JAMA. 1999 ; 282 : 1458-1465.
5. CHUTE C.G., PANSER L.A., GIRMAN C.J., OESTERLING J.E., GUESS H.A., JACOBSEN S.J., LIEBER M.M. : The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol., 1993 ; 150 : 85-89.
6. DE LA ROSETTE J.J., ALIVIZATOS G., MADERSBACHER S., PERACHINO M., THOMAS D., DESGRANDCHAMPS F., DE WILDT M. : European Association of Urology. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur. Urol., 2001 ; 40 : 256-263.
7. GUESS H.A., ARRIGHI H.M., METTER E.J., FOZARD J.L. : Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate, 1990 ; 17 : 241-246.
8. KHOURY S. : 5th International Consultation on BPH. Proceedings 2000, page 175. Health Publication Ltd.
9. ROEHRBORN C.G., BARTSCH G., KIRBY R., ANDRIOLE G., BOYLE P., DE LA ROSETTE J., PERRIN P., RAMSEY E., NORDLING J., DE CAMPOS FREIRE G., ARAP S. : Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology, 2001 ; 58 : 642-650.
10. ROEHRBORN C.G., BOYLE P., BERGNER D., GRAY T., GITTELMAN M., SHOWN T., MELMAN A., BRACKEN R.B., DEVERE WHITE R., TAYLOR A., WANG D., WALDSTREICHER J. : Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate : results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology, 1999 ; 54 : 662-669.
11. ROEHRBORN C.G., BRUSKEWITZ R., NICKEL G.C., GLICKMAN S., COX C., ANDERSON R., KANDZARI S., HERLIHY R., KORNITZER G., BROWN B.T., HOLTGREWE H.L., TAYLOR A., WANG D., WALDSTREICHER J. : Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes.The PLESS Study Group. Eur. Urol., 2000 ; 37 : 528-536.
12. ROEHRBORN C.G., MALICE M., COOK T.J., GIRMAN C.J. : Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology, 2001 ; 58 : 210-216.
13. ROEHRBORN C.G., MCCONNELL J., BONILLA J., ROSENBLATT S., HUDSON P.B., MALEK G.H., SCHELLHAMMER P.F., BRUSKEWITZ R., MATSUMOTO A.M., HARRISON L.H., FUSELIER H.A., WALSH P., ROY J., ANDRIOLE G., RESNICK M., WALDSTREICHER J. : Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J. Urol., 2000 ; 163 : 13-20.
14. ROEHRBORN C.G., MCCONNELL J.D., SALTZMAN B., BERGNER D., GRAY T, NARAYAN P., COOK T.J., JOHNSON-LEVONAS A.O., QUEZADA W.A., WALDSTREICHER J., PLESS STUDY GROUP: Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur. Urol., 2002 ; 42 : 1-6.
15. VERHAMME K.M., DIELEMAN J.P., BLEUMINK G.S., VAN DER LEI J., STURKENBOOM M.C., ARTIBANI W., BEGAUD B., BERGES R., BORKOWSKI A., CHAPPEL C.R., COSTELLO A., DOBRONSKI P., FARMER R.D., JIMENEZ CRUZ F., JONAS U., MACRAE K., PIENTKA L., RUTTEN F.F., VAN SCHAYCK C.P., SPEAKMAN M.J., STURKENBOOM M.C., TEILLAC P., TUBARO A., VALLANCIEN G., VELA NAVARRETE R. : Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur. Urol., 2002 ; 42 : 323-328.